BRPI0409249A - formulação estabilizante para as composições das imunoglobulinas g na forma lìquida e na forma liofilizada - Google Patents

formulação estabilizante para as composições das imunoglobulinas g na forma lìquida e na forma liofilizada

Info

Publication number
BRPI0409249A
BRPI0409249A BRPI0409249-0A BRPI0409249A BRPI0409249A BR PI0409249 A BRPI0409249 A BR PI0409249A BR PI0409249 A BRPI0409249 A BR PI0409249A BR PI0409249 A BRPI0409249 A BR PI0409249A
Authority
BR
Brazil
Prior art keywords
compositions
immunoglobulin
stabilizing formulation
liquid form
lyophilized
Prior art date
Application number
BRPI0409249-0A
Other languages
English (en)
Inventor
Annie Bardat
Edith Begin
Nassirah Khandoudi
Olivier Just
Sami Chtouri
Roland Schmitthaeusler
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0409249A publication Critical patent/BRPI0409249A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"FORMULAçãO ESTABILIZANTE PARA AS COMPOSIçõES DAS IMUNOGLOBULINAS G NA FORMA LìQUIDA E NA FORMA LIOFILIZADA". A invenção se refere a uma formulação estabilizante para as composições das imunoglobulinas G compreendendo um açúcar alcoólico, glicina e um detergente não iónico apropriado para a estabilização das composições da iminoglobulina G na forma líquida e na forma liofilizada. A invenção se refere ainda a uma composição das imunoglobulinas G na forma líquida e na forma liofilizada compreendendo a dita formulação estabilizante.
BRPI0409249-0A 2003-04-09 2004-04-08 formulação estabilizante para as composições das imunoglobulinas g na forma lìquida e na forma liofilizada BRPI0409249A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0304388A FR2853551B1 (fr) 2003-04-09 2003-04-09 Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
PCT/FR2004/000871 WO2004091656A2 (fr) 2003-04-09 2004-04-08 Formulation stabilisante pour compositions d'immunoglobulines G sous forme liquide et sous forme lyophilisEe

Publications (1)

Publication Number Publication Date
BRPI0409249A true BRPI0409249A (pt) 2006-04-18

Family

ID=33041731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409249-0A BRPI0409249A (pt) 2003-04-09 2004-04-08 formulação estabilizante para as composições das imunoglobulinas g na forma lìquida e na forma liofilizada

Country Status (12)

Country Link
US (2) US8388954B2 (pt)
EP (1) EP1610819B1 (pt)
JP (2) JP5357391B2 (pt)
AU (1) AU2004229205B2 (pt)
BR (1) BRPI0409249A (pt)
CA (1) CA2521909C (pt)
DK (1) DK1610819T3 (pt)
ES (1) ES2424992T3 (pt)
FR (1) FR2853551B1 (pt)
IL (1) IL171123A (pt)
PL (1) PL1610819T3 (pt)
WO (1) WO2004091656A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
FR2899112B1 (fr) 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
KR101140483B1 (ko) * 2007-05-02 2012-07-11 에프. 호프만-라 로슈 아게 단백질을 안정화시키는 방법
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
FR2939667B1 (fr) 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
WO2010111255A1 (en) * 2009-03-23 2010-09-30 Hememics Biotechnologies, Inc. Desiccated biologics and methods of preparing the same
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
FR2952826B1 (fr) 2009-11-20 2012-04-06 Lab Francais Du Fractionnement Utilisation d'immunoglobulines polyvalentes pour traiter une cirrhose hepatique alcoolique ou metabolique
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
JP2014202667A (ja) * 2013-04-08 2014-10-27 株式会社島津製作所 抗体医薬用粒子径分布測定装置及び抗体医薬の粒子径分布測定方法
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
CN113597532B (zh) 2019-03-14 2023-02-17 泰尔茂比司特生物技术有限公司 冻干容器填充固定装置、系统及使用方法
CN112878994A (zh) * 2021-03-26 2021-06-01 中石油煤层气有限责任公司 一种模拟井筒与地层物质交流的实验装置

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4586585A (en) 1985-08-15 1986-05-06 Zaner Leonard A Longitudinally extensible stringer and stairway
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
HUT54308A (en) * 1989-04-04 1991-02-28 Lilly Co Eli Process for producing immunoglobulin conjugates and medicaments comprising same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
JP3395181B2 (ja) 1991-07-26 2003-04-07 東レ株式会社 造血幹細胞増加剤
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
FR2708467B1 (fr) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
IT1271088B (it) 1994-11-24 1997-05-26 Dompe Spa Uso di fattore di crescita degli epatociti per indurre la proliferazione e differenziazione di cellule emopoietiche
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6143292A (en) 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19549232C2 (de) 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
AU6914998A (en) * 1997-04-07 1998-10-30 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
US6511958B1 (en) 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
ATE357509T1 (de) 1997-09-29 2007-04-15 Point Therapeutics Inc Stimulierung von hämatopoietischen zellen im vitro
US6132708A (en) 1997-10-10 2000-10-17 Oregon Health Sciences University Liver regeneration using pancreas cells
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO1999048524A1 (en) 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
JP5025058B2 (ja) 2001-09-28 2012-09-12 株式会社カネカ バルーンカテーテル
JP2005532395A (ja) * 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション 新規な安定処方
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee

Also Published As

Publication number Publication date
FR2853551A1 (fr) 2004-10-15
WO2004091656A2 (fr) 2004-10-28
EP1610819B1 (fr) 2013-06-19
ES2424992T3 (es) 2013-10-10
AU2004229205B2 (en) 2008-11-13
US20130202585A1 (en) 2013-08-08
CA2521909C (fr) 2012-11-06
WO2004091656A3 (fr) 2005-01-27
IL171123A (en) 2010-02-17
US20070036779A1 (en) 2007-02-15
JP2011184454A (ja) 2011-09-22
JP2006522780A (ja) 2006-10-05
JP5357391B2 (ja) 2013-12-04
US9463241B2 (en) 2016-10-11
PL1610819T3 (pl) 2013-10-31
AU2004229205A1 (en) 2004-10-28
US8388954B2 (en) 2013-03-05
FR2853551B1 (fr) 2006-08-04
EP1610819A2 (fr) 2006-01-04
CA2521909A1 (fr) 2004-10-28
DK1610819T3 (da) 2013-09-02

Similar Documents

Publication Publication Date Title
BRPI0409249A (pt) formulação estabilizante para as composições das imunoglobulinas g na forma lìquida e na forma liofilizada
WO2007124299A8 (en) Antagonist anti-cd40 antibody pharmaceutical compositions
ECSP045154A (es) Composiciones de fórmula para infantes que comrende cantidades aumentadas de alfa - lactalbumin
BRPI0515316A (pt) compostos de imidazoquinolina
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2006103037A3 (de) ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2
JP2006522780A5 (ja) 液状形態及び凍結乾燥形態の免疫グロブリンｇ組成物用安定化配合物
ES2311803T3 (es) Composiciones embolicas de silicie pirogena.
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
MX2010003792A (es) Formulacion para lavado de platos que comprende una mezcla de policarboxilatos hidrofobicamente modificados y policarboxilatos hidrofilicamente modificados.
MEP21908A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
FR2924607B1 (fr) Composition cosmetique renfermant un gel anhydre et un ester de glyceryle
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
BRPI0519414A2 (pt) composiÇço oral, composiÇço em pasta ou gel, e, mÉtodos para inibir crescimento bacteriano na cavidade oral, e para manter saéde sistÊmica
NO20073762L (no) Visko-supplementsammensetning og fremgangsmater
DE50305507D1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
WO2007011884A3 (en) Dough compositions for extended shelf life baked articles
WO2007057873A3 (en) Novel compositions to improve gut health and animal performance and methods of making the same
DK1589834T3 (da) Enteral komposition til forebyggelse og/eller behandling af sepsis
ATE452142T1 (de) Aufgereinigte arabinogalactanprotein-(agp- )zusammensetzung
BRPI0513939A (pt) composição, formador de creme e/ou clareador, composição de alimento, processo para a manufatura de uma composição e uso de uma composição
WO2005066086A3 (de) Verwendung von glaskeramikscheiben
EP1957652A4 (en) PRO APOPTOSIS BACTERIA AND COMPOSITIONS FOR THE SUPPLY AND EXPRESSION OF ANTIGENES
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2006079722A3 (fr) Compositions pour la lyophilisation de proteines

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06T Formal requirements before examination
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements